masitinib (AB1010)

DRUG5 trials

Sponsors

AB Science

Conditions

Alzheimer's DiseaseMastocytosisMetastatic Colorectal CancerMultiple MyelomaRheumatoid Arthritis

Phase 2

Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

CompletedNCT00831922

AB ScienceRheumatoid Arthritis

Start: 2004-09-30Updated: 2018-12-11

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

CompletedNCT00831974

AB ScienceMastocytosis

Start: 2004-10-31Updated: 2018-12-11

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

CompletedNCT00866138

AB ScienceMultiple Myeloma

Start: 2005-02-28End: 2011-01-31Updated: 2019-12-03

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

CompletedNCT00976118

AB ScienceAlzheimer's Disease

Start: 2006-02-28End: 2009-02-28Updated: 2018-12-13

Phase 3

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

TerminatedNCT02605044

AB ScienceMetastatic Colorectal Cancer

Start: 2014-01-31End: 2017-12-31Updated: 2019-02-11

Related Papers

Calcium handling: a strategy to fight neurodegeneration in Alzheimer’s disease

Neural Regeneration Research2023-04-131 citations

Multi-targeted anti-inflammatory drugs for the treatment of neurological disorders

Neural Regeneration Research2022-09-213 citations

Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.

2011-04-19120 citations

Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.

2009-06-2351 citations